Axogen, Inc. to Participate at Upcoming February Investor Conferences
February 04 2021 - 7:00AM
Axogen, Inc. (NASDAQ: AXGN), a global leader in
developing and marketing innovative surgical solutions for damage
or discontinuity to peripheral nerves, today announced it will
participate in two investor conferences in February.
Karen Zaderej, chairman, CEO, and president, will participate in
a fireside chat at the BTIG Virtual MedTech, Digital Health, Life
Science & Diagnostic Tools Conference on Thursday, February 18,
2021 at 9:00 a.m. ET.
Ms. Zaderej will also participate in a fireside
discussion at the 10th Annual SVB Leerink Global Healthcare
Conference to be held virtually this year. The discussion is
scheduled for Wednesday, February 24, 2021 at 2:20 p.m. ET.
Both discussions will be webcast live and can be
accessed through the Investors page at www.axogeninc.com. For those
not available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.axogeninc.com.
About AxogenAxogen (AXGN) is the leading
company focused specifically on the science, development and
commercialization of technologies for peripheral nerve regeneration
and repair. Axogen employees are passionate about helping to
restore peripheral nerve function and quality of life to patients
with physical damage or transection to peripheral nerves by
providing innovative, clinically proven and economically effective
repair solutions for surgeons and health care providers. Peripheral
nerves provide the pathways for both motor and sensory signals
throughout the body. Every day, people suffer traumatic injuries or
undergo surgical procedures that impact the function of their
peripheral nerves. Physical damage to a peripheral nerve, or
the inability to properly reconnect peripheral nerves, can result
in the loss of muscle or organ function, the loss of sensory
feeling, or the initiation of pain.
Axogen's platform for peripheral nerve repair features a
comprehensive portfolio of products, including Avance® Nerve Graft,
a biologically active off-the-shelf processed human nerve allograft
for bridging severed peripheral nerves without the comorbidities
associated with a second surgical site; Axoguard® Nerve Connector,
a porcine submucosa extracellular matrix (ECM) coaptation aid for
tensionless repair of severed peripheral nerves; Axoguard® Nerve
Protector, a porcine submucosa ECM product used to wrap and protect
damaged peripheral nerves and reinforce the nerve reconstruction
while preventing soft tissue attachments; Axoguard® Nerve Cap, a
porcine submucosa ECM product used to protect a peripheral nerve
end and separate the nerve from the surrounding environment to
reduce the development of symptomatic or painful neuroma; and
Avive® Soft Tissue Membrane, a processed human umbilical cord
intended for surgical use as a resorbable soft tissue barrier. The
Axogen portfolio of products is available in the United States,
Canada, the United Kingdom, South Korea, and several other European
and international countries.
Contact:Axogen, Inc.Peter Mariani, Chief Financial
OfficerInvestorRelations@axogeninc.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Sep 2023 to Sep 2024